Cancer Research and Treatment

Original Articles

Gynecologic cancer

Plasma Cell-Free DNA in Uterine Cervical Cancer: Therapeutic Monitoring and Prognostic Values after Radical Radiotherapy: Jae Sik Kim, Sunah Yang, Kyeonghun Jeong, Dong-Yun Kim, Kwangsoo Kim, Hyun-Cheol Kang; Cancer Res Treat. 2023;55(2):659-670. Published online December 12, 2022; DOI: https://doi.org/10.4143/crt.2022.1440

Abstract PDF Supplementary Material PubReader ePub

Purpose
In the present study, we aimed to establish a liquid biopsy-based monitoring method using peripheral blood cell-free DNA (cfDNA) for patients with cervical cancer who underwent radical radiotherapy (RT).
Materials and Methods
Twenty-five patients with cervical cancer were prospectively recruited and treated with external beam RT and brachytherapy. In all patients, except one, chemotherapy was administered concurrently during RT. Whole peripheral blood samples were obtained at least twice from each patient. We performed next-generation sequencing (NGS) for the target-captured libraries (67 oncogenes and human papillomavirus [HPV] type 16/18) using 64 plasma cfDNA samples from the 25 participants. The ratio of HPV cfDNA and the variant allele frequency (VAF) in cfDNA was calculated, and their dynamic changes were monitored. The median follow-up duration was 25.4 months.
Results
In total, we identified 21,866 cfDNA variants. ARID1A and frameshift variants occupied the largest portion of altered genes and HIGH-grade variant types, respectively. In most cases, tumor shrinkage was followed by a decrease in the HPV ratio; however, an increase in HPV ratio indicated distant metastasis, despite the reduced tumor size. The initial HPV ratio reflecting the tumor burden was likely associated with treatment outcomes (p = 0.16). We did not determine a role for serial changes in the VAF in cfDNA.
Conclusion
Our findings suggest that the HPV cfDNA ratio, calculated after targeted NGS, may be valuable for monitoring and predicting treatment responses. Accordingly, further validation of these findings is warranted.

Citations

Citations to this article as recorded by

Biopsy‐proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome—Retrospective single‐center cohort study
Christoph Ebner, Ricarda Purtscheller, Barin Feroz, Jana Rieker, Linda Ebner, Mara Mantovan, Sergej Skvortsov, Mario Brüggl, Katharina Leitner, Verena Wieser, Irina Tsibulak, Christian Marth, Alain Gustave Zeimet
Acta Obstetricia et Gynecologica Scandinavica.2026; 105(2): 368. CrossRef
The role of circulating tumor DNA in gynecological cancer management
Min Gao, Pei-Yan Yu, Run-Xuan Li, Chen Chen, Xiao-Feng Cong, Zi-Ling Liu
Frontiers in Oncology.2026;[Epub] CrossRef
Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis
Preetiparna Parida, Ankita Mehta, Elstin Anbu Raj, Shyamala Guruvare, Mahadev Rao, Rama Rao Damerla, Shirley Lewis
Critical Reviews in Oncology/Hematology.2026; 220: 105161. CrossRef
The clinical application value of dynamic monitoring of HPV ctDNA in concurrent chemoradiotherapy for locally advanced cervical cancer
Hanqun Zhang, Xiaoqing Luo, Jia Jiang, Cui Zhang, Libo Li, Yanping Chen, Yuting Zeng, Fulin Zhou, Yong Liu, Yuncong Liu, Yong Li
npj Precision Oncology.2026;[Epub] CrossRef
Prognostic Value of Pretreatment Circulating Tumor HPV DNA Load in HPV-Associated Cancers: A Systematic Review and Meta-Analysis
Iwona Agnieszka Jabłońska, Marcin Goławski, Dorota Ścieglińska, Urszula Kacorzyk, Natalia Wojciuszkiewicz, Tomasz Wojciech Rutkowski, Agnieszka Maria Mazurek
International Journal of Molecular Sciences.2026; 27(10): 4263. CrossRef
ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА. РОЛЬ ОПРЕДЕЛЕНИЯ ВИРУСНОЙ НАГРУЗКИ (16 И 18 ТИПОВ) КАК ПРЕДИКТОРА МАЛИГНИЗАЦИИ ЦЕРВИКАЛЬНОГО ЭПИТЕЛИЯ
Вероника Алексеевна Любущенко
Флагман науки.2026; (6(41)): 250. CrossRef
Cell-Free HPV-DNA in Screening, Diagnosis, Prognosis, and Treatment Response Monitoring of Cervical Cancer
Nayara Nascimento Toledo Silva, Ana Carolina Silva Santos, Isadora Oliveira Ansaloni Pereira, Glenda Nicioli da Silva, Angélica Alves Lima
Molecular Diagnosis & Therapy.2025; 29(4): 483. CrossRef
Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer
Preetiparna Parida, Gayathri Baburaj, Mahadev Rao, Shirley Lewis, Rama Rao Damerla
International Journal of Gynecological Cancer.2024; 34(2): 307. CrossRef
Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients
Arthur Daban, Ludivine Beaussire-Trouvay, Émilie Lévêque, Cristina Alexandru, Isabelle Tennevet, Olivier Langlois, Ovidiu Veresezan, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Nasrin Sarafan-Vasseur, Maxime Fontanilles
Translational Oncology.2024; 42: 101897. CrossRef
Cervical Cancer Genetic Profile through Circulating Tumor DNA: What Can We Learn from Blood?
Sevastiani Antonouli, Valentina Di Nisio, Nikoletta Daponte, Athina-Ioanna Daponte, Alexandros Daponte
Biomolecules.2024; 14(7): 825. CrossRef
High throughput sequencing technology and its clinical application in circulating tumor DNA detection in patients with tumors.
Chonghe Xu, Dangui Zhou, Mei Zhu
Investigación Clínica.2024; 65(4): 476. CrossRef

7,460 View
217 Download
12 Web of Science
11 Crossref

General

Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue: Jae Myoung Noh, Yeon Jeong Kim, Ho Yun Lee, Changhoon Choi, Won-Gyun Ahn, Taeseob Lee, Hongryull Pyo, Jee Hyun Park, Donghyun Park, Woong-Yang Park; Cancer Res Treat. 2022;54(1):40-53. Published online May 25, 2021; DOI: https://doi.org/10.4143/crt.2021.151

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the feasibility of using an anatomically localized, target-enriched liquid biopsy (TLB) in mouse models of lung cancer.
Materials and Methods
After irradiating xenograft mouse with human lung cancer cell lines, H1299 (NRAS proto-oncogene, GTPase [NRAS] Q61K) and HCC827 (epidermal growth factor receptor [EGFR] E746-750del), circulating (cell-free) tumor DNA (ctDNA) levels were monitored with quantitative polymerase chain reaction on human long interspersed nuclear element-1 and cell line-specific mutations. We checked dose-dependency at 6, 12, or 18 Gy to each tumor-bearing mouse leg using 6-MV photon beams. We also analyzed ctDNA of lung cancer patients by LiquidSCAN, a targeted deep sequencing to validated the clinical performances of TLB method.
Results
Irradiation could enhance the detection sensitivity of NRAS Q61K in the plasma sample of H1299-xenograft mouse to 4.5- fold. While cell-free DNA (cfDNA) level was not changed at 6 Gy, ctDNA level was increased upon irradiation. Using double-xenograft mouse with H1299 and HCC827, ctDNA polymerase chain reaction analysis with local irradiation in each region could specify mutation type matched to transplanted cell types, proposing an anatomically localized, TLB. Furthermore, when we performed targeted deep sequencing of cfDNA to monitor ctDNA level in 11 patients with lung cancer who underwent radiotherapy, the average ctDNA level was increased within a week after the start of radiotherapy.
Conclusion
TLB using irradiation could temporarily amplify ctDNA release in xenograft mouse and lung cancer patients, which enables us to develop theragnostic method for cancer patients with accurate ctDNA detection.

Citations

Citations to this article as recorded by

Modulating cell-free DNA biology as the next frontier in liquid biopsies
Shervin Tabrizi, Carmen Martin-Alonso, Kan Xiong, Sangeeta N. Bhatia, Viktor A. Adalsteinsson, J. Christopher Love
Trends in Cell Biology.2025; 35(6): 459. CrossRef
Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas
Leire Balaguer-Lluna, Nagore G. Olaciregui, Rosario Aschero, Claudia Resa-Pares, Sonia Paco, Maria Cuadrado-Vilanova, Victor Burgueño, Merce Baulenas-Farres, Carles Monterrubio, Alejandro Manzanares, Eva Rodríguez, Cinzia Lavarino, Jaume Mora, Angel M. Ca
Journal of Neuro-Oncology.2025; 172(3): 599. CrossRef
Early Dynamics of Circulating Tumor DNA Following Curative Hypofractionated Radiotherapy Related to Disease Control in Lung Cancer
Kyungmi Yang, Jae Myoung Noh, Yeon Jeong Kim, Hongryull Pyo
Diagnostics.2025; 15(10): 1198. CrossRef
Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives
Ekaterina S. Kuligina, Grigoriy A. Yanus, Evgeny N. Imyanitov
Exploration of Targeted Anti-tumor Therapy.2025;[Epub] CrossRef
The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy
Ashley Horne, Amelia Payne, Harry Crawford, Clare Dempsey, Hitesh Mistry, Gareth Price, Corinne Faivre-Finn
BioMed.2025; 5(4): 27. CrossRef
Индукция выброса циркулирующей опухолевой ДНК в кровоток с помощью локального облучения опухолевого очага у пациентов с немелкоклеточным раком легкого
С.Ю. Смирнов, А.В. Медведь, А.М. Пашкевич, Ю.С. Карпейчик, С.Н. Пивоварчик, Т.Г. Вахомчик, П.Е. Короткевич, Е.И. Субоч, А.С. Портянко
Евразийский онкологический журнал.2025; 13(4): 321. CrossRef
Surpassing sensitivity limits in liquid biopsy
Tina Moser, Ellen Heitzer
Science.2024; 383(6680): 260. CrossRef
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Carmen Martin-Alonso, Shervin Tabrizi, Kan Xiong, Timothy Blewett, Sainetra Sridhar, Andjela Crnjac, Sahil Patel, Zhenyi An, Ahmet Bekdemir, Douglas Shea, Shih-Ting Wang, Sergio Rodriguez-Aponte, Christopher A. Naranjo, Justin Rhoades, Jesse D. Kirkpatric
Science.2024;[Epub] CrossRef
Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer
Ashley Horne, Ken Harada, Katherine D. Brown, Kevin Lee Min Chua, Fiona McDonald, Gareth Price, Paul Martin Putora, Dominic G. Rothwell, Corinne Faivre-Finn
Journal of Thoracic Oncology.2024; 19(8): 1164. CrossRef
Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
Benedetta Cena, Emmanuel Melloul, Nicolas Demartines, Olivier Dormond, Ismail Labgaa
International Journal of Molecular Sciences.2022; 23(10): 5343. CrossRef
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden
Kwang Seob Lee, Jieun Seo, Choong-Kun Lee, Saeam Shin, Zisun Choi, Seungki Min, Jun Hyuek Yang, Woo Sun Kwon, Woobin Yun, Mi Ri Park, Jong Rak Choi, Hyun Cheol Chung, Seung-Tae Lee, Sun Young Rha
Clinical Chemistry.2022; 68(12): 1519. CrossRef

11,002 View
311 Download
9 Web of Science
11 Crossref

First
Prev
Page of 1
Next
Last

Search